Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Hubei Jumpcan Pharmaceutical Co., Ltd.

Market Cap 25.42B 3.75B 3.25B 2.98B 2.81B 5.22B 358B 5.31B 35.44B 13.79B 173B 14.09B 13.78B 601B P/E ratio 2026 *
-
P/E ratio 2027 * -
Enterprise value 14.43B 2.13B 1.85B 1.69B 1.59B 2.97B 203B 3.01B 20.12B 7.83B 98.19B 8B 7.83B 341B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
37.5%
Yield 2026 *
-
Yield 2027 * -
1 day-1.46%
1 week-0.54%
Current month+0.18%
1 month-3.63%
3 months-0.61%
6 months+1.32%
Current year+4.87%
1 week 26.81
Extreme 26.81
28.28
1 month 26.6
Extreme 26.6
29.6
Current year 24.12
Extreme 24.12
29.6
1 year 24.12
Extreme 24.12
29.6
3 years 23.85
Extreme 23.85
45.18
5 years 14.37
Extreme 14.37
45.18
10 years 14.37
Extreme 14.37
54.97
Manager TitleAgeSince
Chief Executive Officer 43 2019-12-19
Director of Finance/CFO 58 2022-09-25
Investor Relations Contact 29 2024-07-21
Director TitleAgeSince
Chairman 69 2014-03-09
Director/Board Member 64 2014-03-09
Director/Board Member 43 2014-03-09
Date Insider Type Main position Quantity % Market Cap.
Nov. 30Buy

Director

30,000 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
-1.46%-0.54%+0.73%-5.84% 3.75B
+1.41%-0.64%-12.54%-6.18% 13.04B
-2.08%-5.88%-34.18%-56.67% 4.96B
-1.01%-1.25%-10.61%-3.73% 4.66B
-1.79%-3.97%+11.69%-22.25% 3.85B
-1.95%-5.39%+4.35%-42.95% 3.72B
-1.41%-2.44%-14.17%-7.72% 3.09B
-1.73%-2.44%-10.36%-31.40% 2.3B
-0.78%-1.42%-10.30%+31.81% 1.79B
-1.85%-5.44%-17.70%-17.16% 1.69B
Average -1.26%-2.79%-9.31%-16.21% 4.29B
Weighted average by Cap. -0.68%-2.14%-10.14%-16.68%

Financials

2026 *2027 *
Net sales - -
Net income 1.72B 254M 220M 202M 190M 354M 24.25B 360M 2.4B 935M 11.73B 956M 935M 40.79B -
Net Debt - -
Logo Hubei Jumpcan Pharmaceutical Co., Ltd.
Hubei Jumpcan Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of drugs. The Company focuses on the research and development, production and sales of drugs in the fields of pediatrics, respiratory system, digestive system and gynecology. The Company's main products include Xiao’er Chiqiao Qingre Keli, Pudilan Anti-inflammatory Oral Liquid, Huanglong Anti-cough Keli, Iron Proteinsuccinylate Oral Solution, Fuyanshu Capsules and others. The Company's products are mainly used in children's wind-heat cold with stagnation, clearing heat and detoxification, upper respiratory tract infectious diseases, acute and chronic bronchitis, gastrointestinal diseases, gynecology and other fields. The Company mainly operates its businesses in the domestic market.
Employees
5,026
Date Price Change Volume
26-06-08 27.58 ¥ -1.46% 5,352,497
26-06-05 27.99 ¥ +1.74% 3,954,459
26-06-04 27.51 ¥ -0.29% 2,931,173
26-06-03 27.59 ¥ -1.92% 4,051,886
26-06-02 28.13 ¥ +1.44% 7,295,018
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
27.58
Average target price
-

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 600566 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW